STOCK TITAN

Windward Bio: OrbiMed holds 3.56M Series A shares

Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

Windward Bio Group AG (WWB) Form 3 lists OrbiMed Private Investments IX, LP as record holder of 3,561,936 Series A preferred shares, 1,611,008 Series B preferred shares, 216,668 warrants and 531,632 common shares as of November 12, 2026. The preferred shares convert on a 1-to-1 basis into common shares immediately before the initial public offering closes; the warrants are exercisable at $0.02 and expire May 12, 2036. OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC may be deemed to have voting and investment power, but disclaim beneficial ownership except to the extent of any pecuniary interest.

Insider ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC
Role Director, 10% Owner | Director, 10% Owner
Type Security Shares Price Value
Holding Series A Preferred Shares F3, F1, F2 -- -- --
Holding Series B Preferred Shares F3, F1, F2 -- -- --
Holding Warrants (right to buy) F5, F4, F1, F2 -- -- --
Holding Common Shares F1, F2 -- -- --
Holdings: Series A Preferred Shares — 3,561,936 shares (Indirect, See footnotes); Series B Preferred Shares — 1,611,008 shares (Indirect, See footnotes); Warrants (right to buy) — 216,668 warrants (Indirect, See footnotes); Common Shares — 531,632 shares (Indirect, See footnotes)
Footnotes (5)
  1. F1. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
  2. F2. This report on Form 3 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
  3. F3. Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
  4. F4. The warrants are fully vested and exercisable.
  5. F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
Series A Preferred Shares 3,561,936 shares Held of record by OrbiMed Private Investments IX, LP; converts into common shares on a 1-to-1 basis immediately before the initial public offering closes.
Series B Preferred Shares 1,611,008 shares Held of record by OrbiMed Private Investments IX, LP; converts into common shares on a 1-to-1 basis immediately before the initial public offering closes.
Warrants for Common Shares 216,668 warrants Held of record by OrbiMed Private Investments IX, LP; fully vested and exercisable; expire May 12, 2036.
Warrant Exercise Price $0.02 per share The exercise price is in U.S. dollars.
Common Shares 531,632 shares Held of record by OrbiMed Private Investments IX, LP.
initial public offering financial
"immediately prior to the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
voting and investment power regulatory
"may be deemed to have voting and investment power"
pecuniary interest regulatory
"except to the extent of its pecuniary interest therein"
fully vested and exercisable financial
"The warrants are fully vested and exercisable"
beneficial ownership regulatory
"disclaims beneficial ownership of the securities reported herein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How will WWB’s Series A and Series B preferred shares convert?

Each Series A and Series B preferred share converts into one common share immediately before the closing of the initial public offering.

What are the terms of the WWB warrants reported by OrbiMed?

The 216,668 warrants are fully vested and exercisable at $0.02 per share and expire May 12, 2036. The exercise price is in U.S. dollars.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC

(Last)(First)(Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/12/2026
3. Issuer Name and Ticker or Trading Symbol
WINDWARD BIO GROUP AG [ WWB ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares531,632ISee footnotes(1)(2)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Preferred Shares (3) (3)Common Shares3,561,936(3)ISee footnotes(1)(2)
Series B Preferred Shares (3) (3)Common Shares1,611,008(3)ISee footnotes(1)(2)
Warrants (right to buy) (4)05/12/2036Common Shares216,668$0.02(5)ISee footnotes(1)(2)
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC

(Last)(First)(Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
OrbiMed Capital GP IX LLC

(Last)(First)(Middle)
601 LEXINGTON AVENUE
54TH FLOOR

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
2. This report on Form 3 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
3. Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
4. The warrants are fully vested and exercisable.
5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC11/12/2026
/s/ Carl L. Gordon, Member of OrbiMed Capital GP IX LLC11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading